A promising new weapon in the global fight against yellow fever has emerged. The virus is transmitted to humans through the bites of infected mosquitoes and causes symptoms ranging from mild feverish aches and pains to severe liver disease.
According to a recent study, a new yellow fever vaccine, called vYF by Sanofi, has been shown to work as well as the currently approved vaccine, YF-VAX. Yellow fever causes between 29,000 and 60,000 deaths annually, despite the existence of safe vaccines.
Previous severe outbreaks in Central Africa and Brazil have depleted global emergency supplies, forcing the use of fractional doses. Because there are no antiviral drugs against yellow fever, vaccination is the only effective defense. The vYF vaccine was developed by Sanofi; Unlike traditional vaccines, vYF is grown in Vero cells. This new method ensures higher yields and more efficient production, directly addressing the global shortage of doses. A total of 485 healthy adults (aged 18 to 60) participated in the clinical trial.
This randomized, observer-blind study directly compared the new vYF vaccine to the established VF-VAX. A total of 329 participants received vFF, while 156 participants received VF-VAX. Key results showed that 99.7% of the vYF group developed protective antibodies within 28 days, almost identical to the 99.4% success rate of the YF-VAX group.
In both groups, antibody levels peaked on day 29 and declined at a similar rate over the following year. No major safety issues have been identified. Side effects were mild and no participant withdrew due to side effects. Once it receives final approval, vYF will provide a scalable, high-volume tool to prevent future vaccine shortages and control global outbreaks.
